Substance- or Medication-Induced Anxiety Disorder: Causes, Diagnosis, and Treatment
Updated: Oct 8
Author: Ukrainian Psychological Hub · Published: September 30, 2026 · Editorial Policy
Substance- or medication-induced anxiety disorder is a clinical diagnosis used when prominent anxiety or panic is judged to be caused by the physiological effects of a substance, medication, intoxication, or withdrawal rather than being better explained by an independent anxiety disorder. In DSM-5-TR it belongs to the Anxiety Disorders chapter; ICD-11 organizes substance-induced anxiety differently, primarily through substance-specific categories in the Disorders due to substance use or addictive behaviours grouping. This difference in classification matters because a symptom such as nervousness after caffeine, a medication side effect, an intoxication syndrome, a withdrawal syndrome, a panic attack, and a formal induced anxiety disorder are related concepts but are not interchangeable. Merck Manual Professional summarizes the DSM-5-TR placement, while the WHO ICD-11 CDDR provides the current ICD-11 framework.
The central diagnostic question is causation: did the exposure plausibly produce the anxiety syndrome, and does the timing support that conclusion? A clinician also has to ask whether the symptoms began before the exposure, recur when the substance is absent, persist beyond the expected intoxication or withdrawal period, or are better explained by another psychiatric or medical condition. SAMHSA’s guidance on co-occurring mental and substance-related disorders emphasizes this temporal and differential-diagnostic approach rather than treating every anxiety symptom in a person who uses substances as substance-induced. SAMHSA TIP 42 is a useful clinical reference for that distinction.
What Is Substance- or Medication-Induced Anxiety Disorder?
The diagnosis describes a clinically significant anxiety syndrome in which fear, anxiety, or panic is prominent and there is persuasive evidence that a substance or medication is the direct physiological cause. The relevant exposure may be prescribed treatment, over-the-counter medication, recreational or nonmedical drug use, intoxication, or withdrawal. The diagnosis is not a moral judgment about drug use and it does not imply that a person has a substance use disorder.
DSM-5-TR retains substance/medication-induced anxiety disorder within the anxiety-disorder classification. The American Psychiatric Association’s own DSM-5-TR coding updates, for example, include substance-specific induced anxiety diagnoses such as opioid-induced anxiety disorder. APA’s DSM-5-TR code update page documents this current classification.
ICD-11 does not reproduce the DSM umbrella in exactly the same way. It places substance-induced anxiety disorders under substance-specific categories within Disorders due to substance use or addictive behaviours. Examples include alcohol-induced, cannabis-induced, sedative/hypnotic/anxiolytic-induced, cocaine-induced, stimulant-induced, caffeine-induced, hallucinogen-induced, and other substance-induced anxiety disorders. A 2025 taxonomy review of ICD-11 explicitly describes this architecture and contrasts it with the anxiety or fear-related disorders chapter. Domschke and Zwanzger (2025) provide a current peer-reviewed comparison.
Anxiety symptoms are not automatically an anxiety disorder
Many substances and medications can produce transient nervousness, tremor, palpitations, insomnia, restlessness, or a feeling of being “on edge.” Those are symptoms. A formal disorder requires a clinically meaningful syndrome, not merely the presence of one expected adverse effect. The broader English Hub overview, Anxiety Symptoms: Emotional, Cognitive, Physical, and Behavioral Signs, explains the symptom layer; the present article owns the causal diagnostic construct.
The distinction is especially important with common exposures. A cup of coffee that produces mild jitteriness does not establish caffeine-induced anxiety disorder. A temporary increase in restlessness after starting a medicine does not automatically establish medication-induced anxiety disorder. Diagnosis depends on severity, impairment or distress, timing, pharmacological plausibility, the wider clinical picture, and exclusion of better explanations.
Normal anxiety, fear, worry, and stress responses can also occur during illness, sleep loss, pain, conflict, or an unpleasant drug experience. They become part of a clinical disorder only when the relevant diagnostic threshold and causal pattern are met. “Anxiety attack” is an informal expression without a single standardized DSM-5-TR or ICD-11 definition; a panic attack is a defined symptom construct, but a panic attack by itself does not identify the underlying disorder.
What Symptoms Can It Cause?
The presentation can resemble other anxiety syndromes. People may experience intense apprehension, uncontrollable nervousness, fear, panic attacks, a sense of impending danger, irritability, restlessness, difficulty concentrating, insomnia, or avoidance that develops because certain sensations or contexts have become frightening. Physical symptoms can include palpitations, a rapid pulse, sweating, tremor, nausea, chest tightness, shortness of breath, dizziness, tingling, or gastrointestinal distress. These manifestations overlap substantially with ordinary anxiety and with primary anxiety disorders. Merck’s 2026 professional overview describes the broad cognitive, behavioral, autonomic, respiratory, cardiac, gastrointestinal, and musculoskeletal manifestations of anxiety.
That overlap is exactly why symptoms alone cannot establish cause. Palpitations after stimulant use may be part of anxiety, a direct cardiovascular drug effect, an arrhythmia, or a mixture of these. Shortness of breath may occur with panic, but it can also reflect asthma, pulmonary disease, medication toxicity, or another medical problem. Chest pain, fainting, seizures, severe confusion, high fever, or marked neurological symptoms require medical assessment rather than an online assumption that anxiety explains them.
Which Substances Can Cause Anxiety?
Authoritative clinical references and the DSM/ICD frameworks recognize multiple substance classes capable of producing anxiety during use, intoxication, or withdrawal. SAMHSA’s substance-induced mental-disorders table includes alcohol, caffeine, cannabis, hallucinogens, inhalants, opioids, sedatives, and stimulants among substances that can be associated with induced anxiety disorders. SAMHSA TIP 42’s substance table provides the category-level overview. The strength, timing, and mechanism of evidence vary substantially by substance.
Caffeine
Caffeine is one of the clearest everyday examples of a substance that can increase anxiety symptoms. Experimental and observational evidence supports a dose-related anxiogenic effect, with substantial individual variability related to habitual use, sensitivity, sleep, and dose. A 2024 meta-analysis found higher anxiety after caffeine exposure in healthy participants, particularly at higher doses. Liu et al. (2024) synthesized 14 study samples from eight articles. A newer systematic review of 27 studies also concluded that the overall evidence predominantly supports a dose-dependent increase in anxiety symptoms, while noting heterogeneity and the possible contribution of caffeine-related insomnia. Nascimento et al. (2026) provides that updated review.
The clinical boundary remains crucial: caffeine can increase anxiety without producing a formal disorder. Diagnosis depends on a clinically significant syndrome and a convincing causal relationship, not the mere fact that a person consumed coffee, tea, an energy drink, pre-workout products, or another caffeine source.
Cannabis and THC
Cannabis can produce acute anxiety, panic, paranoia, and uncomfortable bodily sensations in some people, particularly with THC-containing products and at higher exposures. At the same time, the long-term relationship between cannabis use and anxiety disorders is complicated by self-medication, shared risk factors, product composition, dose, frequency, and confounding. A recent critical systematic review found an association between cannabis use or cannabis use disorder and anxiety but concluded that causal pathways remain difficult to establish and that self-medication may explain an important part of the relationship. Beletsky et al. (2024) is therefore better evidence for a nuanced claim than for the blanket statement that cannabis “causes anxiety disorders.”
For the induced-disorder diagnosis, the relevant question is narrower: did anxiety or panic emerge in a temporal pattern consistent with cannabis intoxication or withdrawal, and is cannabis pharmacologically capable of explaining the syndrome in this person? An acute THC-related panic episode can be psychologically intense and still be different from panic disorder, which requires its own diagnostic pattern.
Cocaine, amphetamines, methamphetamine, and other stimulants
Stimulants can increase sympathetic arousal, heart rate, blood pressure, wakefulness, agitation, fear, and panic-like symptoms. Cocaine and amphetamine-type stimulants are well-established causes of anxiety during intoxication, and anxiety can also occur during stimulant withdrawal. Severe stimulant intoxication can involve cardiovascular, neurological, psychiatric, and temperature-regulation complications; it is therefore unsafe to label severe agitation, chest symptoms, or altered mental status as “just anxiety.” The ASAM/AAAP Clinical Practice Guideline on Stimulant Use Disorder specifically addresses intoxication, withdrawal, and potentially life-threatening complications.
Alcohol, sedatives, hypnotics, and anxiolytics
Anxiety can emerge during alcohol withdrawal and during withdrawal from sedatives, hypnotics, or anxiolytics. In these situations, anxiety may be part of a broader withdrawal syndrome rather than a stand-alone psychiatric problem. Alcohol withdrawal can progress to seizures or delirium in higher-risk cases, so severity assessment matters. ASAM’s Alcohol Withdrawal Management Guideline treats withdrawal as a medical syndrome requiring risk-based management, not simply as anxiety.
Benzodiazepines illustrate another important boundary. Regular use can produce physical dependence, and abrupt discontinuation or large dose reductions can trigger significant withdrawal symptoms, including anxiety and potentially dangerous complications. The 2025 joint guideline states that people likely to be physically dependent should not have benzodiazepines stopped abruptly; tapering should be individualized and clinically supervised. Brunner et al. (2025) is the current multidisciplinary guideline. Physical dependence, withdrawal, and benzodiazepine use disorder are distinct concepts and should not be collapsed into one label.
Other psychoactive substances
Hallucinogens, MDMA and related drugs, dissociative drugs, inhalants, opioids, synthetic cannabinoids, synthetic cathinones, and multiple-substance exposures can also be associated with anxiety syndromes in the appropriate clinical context. ICD-11’s substance-specific classification reflects this breadth. The exact diagnosis depends on the agent, the clinical state, and whether anxiety exceeds or is separable from the expected intoxication or withdrawal presentation. WHO’s ICD-11 CDDR is the authoritative classification source.
Which Medications Can Cause Anxiety Symptoms?
Prescribed and over-the-counter medications can produce anxiety-like symptoms through direct central nervous system effects, autonomic stimulation, endocrine effects, sleep disruption, interactions, toxicity, or withdrawal. Merck lists examples including beta-agonist asthma treatment such as albuterol, theophylline, stimulants used for ADHD, thyroid hormones, decongestants, phenytoin, levodopa, and corticosteroids among medications that can produce anxiety symptoms in some patients. Merck Manual Professional also emphasizes that clinicians should consider medication causes when evaluating significant anxiety.
This list should be interpreted as a differential-diagnosis prompt, not as a claim that each medication commonly causes a formal anxiety disorder. Dose, indication, treatment duration, interactions, organ function, the underlying medical condition, and individual susceptibility all matter. A medicine may produce palpitations or tremor without causing a psychiatric syndrome, and the disease being treated may itself produce anxiety-like physiology.
Thyroid hormone
Excess thyroid hormone can produce symptoms such as palpitations, tremor, heat intolerance, insomnia, and anxiety-like arousal. Yet replacement-dose levothyroxine should not be portrayed as broadly anxiogenic. A 2026 systematic review found that levothyroxine at replacement doses was generally safe and that reported cardiac or neuropsychiatric adverse effects were more concentrated when thyroid-stimulating hormone was suppressed; many comparisons were not clinically or statistically meaningful. Baskaran et al. (2026) supports checking thyroid status and dose rather than assuming that any anxiety in a person taking levothyroxine is medication-induced.
Corticosteroids
Corticosteroids are widely associated with neuropsychiatric adverse effects, but the anxiety-specific evidence is more mixed than popular summaries often suggest. A 2026 systematic review and meta-analysis of 73 studies found clearer signals for depressive and manic symptoms and did not find a statistically significant association with anxiety across the three studies that directly supported that comparison. The authors rated much of the overall evidence as low or very low certainty. Kusudo et al. (2026) therefore supports careful monitoring while resisting the claim that corticosteroids predictably cause anxiety in every user.
Antidepressant activation or “jitteriness/anxiety”
Some people report early anxiety, agitation, irritability, or jitteriness after starting an antidepressant. This phenomenon has long been described clinically, but the evidence base is heterogeneous and the syndrome is inconsistently defined. A systematic review found reported incidence estimates ranging widely and concluded that robust evidence about incidence, prediction, and management was limited. Sinclair et al. (2009) is still a useful synthesis of this specific phenomenon. Early activation symptoms are not automatically the same thing as DSM-5-TR substance/medication-induced anxiety disorder.
How Can a Substance or Medication Produce Anxiety?
There is no single mechanism. Different exposures act on different neurobiological systems, and the same substance may produce different effects at different doses or phases of use. Stimulant-like agents can increase catecholaminergic activity and autonomic arousal. Caffeine antagonizes adenosine receptors and can increase alerting and sympathetic effects. THC can alter perception, salience, autonomic sensations, and threat processing. Withdrawal from alcohol or sedative drugs can produce rebound central nervous system hyperexcitability after adaptation to chronic depressant effects.
Medication-induced anxiety can also be indirect. A drug may disrupt sleep, cause tremor, accelerate heart rate, alter thyroid physiology, or interact with another medication; those bodily changes can themselves become frightening. This means a clinically useful explanation may involve both pharmacology and learning: the exposure generates bodily arousal, the person interprets the sensations as dangerous, and fear amplifies the experience. That plausible psychological amplification does not erase the physiological trigger.
Mechanism should not be inferred merely from temporal coincidence. People often start medications when they are already ill, stressed, sleep-deprived, in pain, or experiencing symptoms from the condition being treated. Those factors can produce anxiety independently. Strong causal reasoning therefore asks what changed, when it changed, whether the agent is known to produce the effect, whether symptoms change with dose or discontinuation, and whether another explanation fits better.
The same exposure can affect people differently. Dose, rate of dose change, route of administration, metabolism, age, sleep, other drugs, baseline anxiety sensitivity, prior panic, medical conditions, tolerance, and withdrawal history can all modify the response. These are susceptibility factors, not diagnostic criteria; none of them alone establishes that an anxiety syndrome was substance- or medication-induced.
How Is Substance- or Medication-Induced Anxiety Disorder Diagnosed?
There is no blood test that independently proves this psychiatric diagnosis. Diagnosis is clinical and causal. Laboratory testing, toxicology, vital signs, electrocardiography, thyroid testing, metabolic testing, or other investigations may be useful when they answer a specific differential-diagnosis question, but a positive drug screen does not by itself prove that the detected substance caused the anxiety. Merck Manual Professional emphasizes history, timing, medical exclusion, clinically significant distress or dysfunction, and clinical judgment.
Screening and symptom-severity measures can support assessment but cannot establish this diagnosis. A GAD-7 score, for example, can quantify recent anxiety symptoms; it does not determine whether those symptoms were caused by a medication or substance, whether they represent generalized anxiety disorder, or whether another medical or toxicologic explanation is present.
1. Establish the anxiety syndrome
The clinician first identifies what is actually happening: generalized anxiety, recurrent panic attacks, intense fear, autonomic arousal, agitation, insomnia, or another presentation. The severity and functional consequences matter. A transient expected side effect and a disabling anxiety syndrome occupy different clinical levels.
2. Reconstruct the exposure timeline
A high-quality assessment maps symptoms against medication starts and stops, dose increases or decreases, missed doses, intoxication periods, withdrawal periods, changes in caffeine or energy-drink intake, new supplements, nonprescribed drugs, alcohol use, sleep loss, and relevant medical changes. The timeline is often the most informative diagnostic instrument in the case. For the broader diagnostic process, see How Is Anxiety Diagnosed? Assessment, History, and Differential Diagnosis.
3. Ask whether the agent can plausibly produce the syndrome
Temporal sequence is necessary but not sufficient. A clinician considers pharmacology, known adverse effects, withdrawal potential, dose, route, half-life, active metabolites, interactions, and the person’s physiology. Multiple simultaneous exposures make attribution harder. SAMHSA’s co-occurring-disorders guidance explicitly lists substance classes known to mimic or induce anxiety during intoxication or withdrawal. SAMHSA’s differential table illustrates why the agent and phase of exposure must be specified.
4. Test the independent-anxiety-disorder hypothesis
An independent anxiety disorder becomes more plausible when clinically similar episodes clearly preceded the substance or medication, symptoms repeatedly occur when the person is not exposed, or the anxiety persists in a way that is inconsistent with the expected intoxication, withdrawal, or medication time course. Family history and prior psychiatric history can contribute context, but neither proves causation.
5. Exclude medical explanations and dangerous mimics
Anxiety-like symptoms can arise from arrhythmia, hyperthyroidism, asthma, hypoglycemia, medication toxicity, infection, neurological disease, and many other medical conditions. Merck specifically lists several medical conditions that may directly produce anxiety-like syndromes and stresses excluding medical and substance causes during assessment. Merck Manual Professional is a useful differential-diagnosis source. The diagnosis “anxiety disorder due to another medical condition” has its own canonical territory and should not be merged into medication-induced anxiety merely because a person is taking treatment for that illness. For the dedicated medical-causation diagnosis, see Anxiety Disorder Due to Another Medical Condition: Diagnosis and Differential Assessment.
6. Consider delirium and other substance-induced syndromes
Marked confusion, fluctuating attention, disorientation, hallucinations, psychosis, mania, or severe agitation can indicate a different or additional syndrome. DSM and ICD frameworks do not treat anxiety occurring exclusively within delirium as a simple induced anxiety disorder. Stimulant intoxication, alcohol withdrawal, medication toxicity, and other states can produce mixed psychiatric and medical presentations that require urgent assessment.
DSM-5-TR and ICD-11: Why the Labels Do Not Match One-to-One
DSM-5-TR places Substance/Medication-Induced Anxiety Disorder in the Anxiety Disorders chapter alongside generalized anxiety disorder, panic disorder, agoraphobia, social anxiety disorder, specific phobia, separation anxiety disorder, selective mutism, anxiety disorder due to another medical condition, and specified or unspecified residual categories. This is the diagnostic territory summarized in the Hub’s DSM-5-TR Anxiety Disorders: Classification and Diagnostic Categories.
ICD-11 uses a different architecture. Its Anxiety or Fear-Related Disorders grouping contains generalized anxiety disorder, panic disorder, agoraphobia, specific phobia, social anxiety disorder, separation anxiety disorder, selective mutism, and residual categories. Substance-induced anxiety disorders are instead coded within the substance-use chapter under specific substance classes. Secondary anxiety syndrome is located with secondary mental or behavioral syndromes associated with disorders or diseases classified elsewhere. WHO’s ICD-11 CDDR and Domschke and Zwanzger (2025) support this distinction. ICD-11’s substance-induced mental-disorder framework can also apply to use or discontinuation of a psychoactive medication; it does not reproduce DSM-5-TR’s broader substance/medication-induced anxiety disorder label as a one-to-one category for every prescribed agent.
The practical implication is simple: “substance/medication-induced anxiety disorder” is a valid DSM-5-TR clinical label, while ICD-11 may represent the same clinical territory through a different coding structure. Search terminology should not be mistaken for identical nosology. For a direct systems-level comparison, see DSM-5-TR vs ICD-11 Anxiety Disorders: Key Classification Differences and ICD-11 Anxiety Classification: Anxiety or Fear-Related Disorders.
Key Differential Diagnoses
Generalized anxiety disorder
Generalized anxiety disorder involves a persistent pattern of excessive anxiety and worry across domains rather than a syndrome best explained by the direct physiological effects of a substance or medication. A person can have both GAD and substance exposure, and the presence of caffeine, cannabis, alcohol, or prescription medication does not erase an independent disorder.
Panic disorder
A substance can provoke a panic attack. That does not automatically mean the person has panic disorder. Panic disorder has its own diagnostic pattern involving recurrent unexpected panic attacks and persistent concern or behavioral change related to further attacks. A panic attack during stimulant intoxication, cannabis use, medication activation, or withdrawal may be fully real and severe while belonging to a different causal diagnosis.
Anxiety disorder due to another medical condition
This diagnosis is considered when anxiety is judged to be the direct physiological consequence of a medical disease rather than a substance or medication. The distinction can be difficult when disease and treatment change at the same time. For example, hyperthyroidism can produce anxiety-like symptoms, while excessive thyroid-hormone replacement can also produce hyperadrenergic symptoms. The assessment has to separate disease physiology, treatment effects, and an independent anxiety disorder rather than picking one cause by default.
Intoxication and withdrawal syndromes
Anxiety can be one feature of a broader intoxication or withdrawal syndrome. In clinical practice, the diagnosis should reflect the syndrome that best explains the whole presentation. ICD-11 explicitly treats substance-induced mental disorders in relation to substance-specific intoxication and withdrawal states. Severe withdrawal may require medical management even when anxiety is the symptom that brought the person to care.
Substance use disorder
A substance-induced anxiety disorder and a substance use disorder answer different questions. The first concerns a substance causing a clinically significant anxiety syndrome. The second concerns a problematic pattern of use and its consequences. Either may occur without the other, and they can co-occur. Treatment planning changes when dependence, withdrawal risk, compulsive use, overdose risk, or other substance-related harms are present.
Medication adverse effect without a psychiatric disorder
This is one of the most common boundaries. A person may have an adverse drug effect such as restlessness, tremor, insomnia, palpitations, or transient anxiety that warrants dose review without meeting criteria for a psychiatric disorder. Good clinical language preserves that distinction because it affects prognosis, coding, and treatment.
Treatment: What Actually Changes the Outcome?
Treatment begins with the cause and the level of medical risk. There is no single treatment protocol that applies to every substance, every medication, and every withdrawal state. Management of caffeine-related anxiety, stimulant intoxication, alcohol withdrawal, benzodiazepine withdrawal, thyroid-hormone excess, antidepressant activation, and a complex multi-drug interaction are fundamentally different tasks.
Address the causal exposure safely
When a prescribed medication is suspected, the usual next step is clinical review of the indication, timing, dose, interactions, and alternatives. Depending on the drug, a clinician may adjust the dose, change administration timing, switch treatment, treat a contributing medical factor, or taper the medication. People should not abruptly stop a prescribed medication solely because anxiety appeared. Some drugs require gradual dose reduction, and abrupt discontinuation can create a more dangerous withdrawal syndrome.
Benzodiazepines are the clearest example. The 2025 joint guideline recommends gradual, individualized tapering for patients likely to be physically dependent and warns against abrupt discontinuation. Brunner et al. (2025) provides the evidence-informed framework. The same general principle—identify the drug-specific discontinuation risk before stopping—applies across medication safety, even though the tapering method differs by medication.
Treat intoxication or withdrawal as the syndrome it is
When the anxiety occurs during a medically significant intoxication or withdrawal state, treatment targets that state. Severe stimulant intoxication may require acute monitoring and management of cardiovascular, temperature, agitation, or psychiatric complications. ASAM/AAAP’s stimulant guideline gives syndrome-specific guidance. Alcohol withdrawal requires risk assessment and appropriate withdrawal management; ASAM’s alcohol-withdrawal guideline emphasizes that withdrawal management is part of a broader treatment process rather than a complete treatment for alcohol use disorder.
Treat a co-occurring substance use disorder when present
If a substance use disorder is present, treating the anxiety episode without addressing the substance-use pattern can leave the main driver of recurrence untouched. Conversely, clinicians should not withhold treatment for a genuine independent anxiety disorder merely because a substance use disorder is also present. Integrated assessment is designed to identify both. SAMHSA TIP 42 is specifically structured around co-occurring mental and substance-related disorders.
Use anxiety treatment according to the diagnosis that remains
If clinically significant anxiety persists after the causal substance or medication issue has been addressed, the diagnosis should be reassessed. The person may have an independent anxiety disorder, residual conditioned fear of bodily sensations, a medical condition, sleep disruption, another psychiatric disorder, or several contributors. Evidence-based psychotherapy or pharmacotherapy may then be appropriate for the actual diagnosed condition. Evidence from GAD, panic disorder, or social anxiety disorder should not be automatically transferred to substance/medication-induced anxiety disorder as though the disorders were interchangeable.
CBT-based strategies can still be useful for catastrophic interpretations, avoidance, fear of bodily sensations, and coping, particularly when those processes persist after the acute physiological trigger resolves. Their role should be framed as treatment of the person’s current maintaining mechanisms or co-occurring anxiety condition, not as an antidote to intoxication, withdrawal, or medication toxicity.
How Long Does Substance- or Medication-Induced Anxiety Last?
There is no universal duration. The time course depends on the substance or medication, dose, route, half-life, active metabolites, duration of exposure, tolerance, withdrawal physiology, drug interactions, kidney and liver function, sleep loss, and whether an independent anxiety disorder is also present. Acute stimulant- or caffeine-related symptoms may track the period of pharmacological activity; withdrawal-related anxiety can follow a different and sometimes longer course.
Clinically, persistence matters because it changes the differential diagnosis. Anxiety that began long before the exposure, continues well beyond the expected pharmacological or withdrawal window, or recurs repeatedly when the person is not exposed makes an independent anxiety disorder or another cause more plausible. Persistence does not prove an independent disorder by itself; some withdrawal syndromes can be prolonged and some medications have long or complex elimination profiles. The timeline has to be interpreted drug by drug.
When Anxiety After a Substance or Medication Needs Urgent Medical Evaluation
Urgent evaluation is appropriate when anxiety-like symptoms occur with chest pain, severe or worsening shortness of breath, fainting, seizure, severe confusion, delirium, hallucinations, extreme agitation, very high temperature, marked muscle rigidity or abnormal movements, severe blood-pressure changes, suspected overdose, or other signs of medical instability. These features can occur in toxicologic, cardiovascular, neurological, respiratory, or withdrawal emergencies and cannot be safely distinguished from anxiety through symptom matching alone.
Medication reactions can also masquerade as anxiety. Serotonin syndrome, for example, is a potentially life-threatening reaction associated with serotonergic drugs and can include agitation, fast heart rate, high blood pressure, fever, abnormal reflexes, muscle symptoms, and mental-status changes. MedlinePlus provides an authoritative clinical overview. The presence of agitation or anxiety does not make serotonin toxicity an anxiety disorder.
Alcohol and sedative withdrawal deserve particular caution because severe withdrawal can involve seizures or delirium. Likewise, severe stimulant intoxication can produce life-threatening complications. When the medical risk is unclear, the safe question is not “Is this anxiety?” but “Could this be a medical or toxicological emergency?”
What to Do If You Think a Medication or Substance Is Causing Anxiety
A useful first step is to build a precise timeline rather than trying to diagnose yourself from a symptom list. Record when the anxiety began, what changed in the days or weeks before it, medication names and doses, recent dose changes or missed doses, caffeine and energy-drink intake, alcohol use, cannabis or other drug exposure, over-the-counter decongestants, supplements, sleep, physical symptoms, and whether similar episodes occurred before the exposure.
For prescribed medication, contact the prescriber or pharmacist and describe the timing and severity. Do not assume the medication must be stopped immediately; the appropriate response depends on the drug. For nonprescribed substances, disclose what was used, when, how much, and by what route as accurately as possible. That information can be medically important even when use was occasional.
If symptoms are mild and clearly linked to a reversible exposure such as excess caffeine, reducing further exposure and restoring sleep and hydration may be reasonable. If symptoms are intense, recurrent, medically concerning, or associated with dependence or withdrawal risk, clinical evaluation is the appropriate level of care.
Frequently Asked Questions
Is substance- or medication-induced anxiety disorder a real diagnosis?
Yes. DSM-5-TR includes substance/medication-induced anxiety disorder in the Anxiety Disorders chapter, and ICD-11 includes substance-specific induced anxiety disorders within its substance-use classification. The two systems organize the concept differently, but both recognize clinically significant anxiety caused by substances.
Can a prescription medication cause an anxiety disorder?
A prescription can cause anxiety symptoms and, in the right clinical circumstances, can support a diagnosis of medication-induced anxiety disorder. The diagnosis requires more than temporal coincidence: the medication must be capable of causing the syndrome, the timing must fit, and competing explanations must be evaluated. Never stop a prescribed medication abruptly without checking whether discontinuation itself carries risk.
Can caffeine cause an anxiety disorder?
Caffeine can increase anxiety in a dose-dependent manner, and both DSM-related clinical frameworks and ICD-11 recognize caffeine-induced anxiety. Most caffeine-related jitteriness is not automatically a psychiatric disorder. Severity, impairment, timing, and differential diagnosis determine the clinical classification. Nascimento et al. (2026) provides the newest systematic review used in this article.
Can cannabis cause panic attacks?
Yes, cannabis—particularly THC-containing products—can precipitate acute anxiety and panic in some people. A cannabis-related panic attack does not by itself establish panic disorder. Longer-term causal claims about cannabis causing independent anxiety disorders remain less certain because self-medication and shared risk factors complicate the evidence. Beletsky et al. (2024) reviews this mixed literature.
Is withdrawal anxiety the same as an anxiety disorder?
Not necessarily. Anxiety can be a feature of a withdrawal syndrome. Depending on the substance, severity, duration, and classification system, clinicians may diagnose the withdrawal syndrome, a substance-induced anxiety disorder, both relevant conditions, or another diagnosis. Alcohol and benzodiazepine withdrawal can be medically important, so the distinction is not merely semantic.
Can someone have both an independent anxiety disorder and substance-induced anxiety?
Yes. A person can have an established anxiety disorder and also experience additional anxiety caused by intoxication, withdrawal, caffeine, cannabis, stimulants, or a medication. The clinician’s task is to separate baseline symptoms from exposure-linked changes and treat each clinically meaningful problem.
Does a positive drug test prove the anxiety is substance-induced?
No. A toxicology result can establish exposure to a detectable substance or metabolite, but it does not establish psychiatric causation. Interpretation depends on timing, detection windows, dose, clinical state, other substances, medication history, and alternative causes.
Does the diagnosis mean the person has an addiction?
No. Substance/medication-induced anxiety disorder concerns the cause of an anxiety syndrome. Substance use disorder concerns a problematic pattern of substance use. They are separate diagnostic questions and can occur independently or together.
What if anxiety continues after the substance is gone?
Persistent anxiety should trigger reassessment rather than an automatic assumption that the original exposure is still the whole explanation. Possibilities include prolonged withdrawal, an independent anxiety disorder, a medical condition, sleep disruption, conditioned fear of bodily sensations, another psychiatric disorder, or continuing exposure that has not been recognized.
Related Articles